Evidence map›Paper›PMID 30147321›Full record

ArticleNeuropsychiatric disease and treatment2018

Safety and effectiveness of escitalopram in an 8-week open study in Chinese patients with depression and anxiety.

Gang Wang, Xiumin You, Xueyi Wang, Xiufeng Xu, Ludong Bai, Jian Xie, Zhijian Yao, QiZhong Yi, Jun Ma, Jinan Wang and 2 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Neuropsychiatric disease and treatment, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.3field-weighted citation impact, top 36% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 11 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 11 institutions in 2 countries.

Gang WangPsychiatry Department, Beijing Anding Hospital, Capital Medical University, National Clinical Research Center for Mental Disorders, Beijing, China.
Xiumin YouPsychiatry Department, Xianyue Hospital, Xiamen, China.
Xueyi WangPsychiatry Department, Institute of Mental Health of Hebei Medical University, Shijiazhuang, China.
Xiufeng XuPsychiatry Department, Kunming Medical University Affiliated Hospital, Kunming, China.
Ludong BaiPsychiatry Department, Shangdong Province Mental Hospital, Jinan, China.
Jian XiePsychiatry Department, Hangzhou First People Hospital, Hangzhou, China.
Zhijian YaoPsychiatry Department, Nanjing Brain Hospital, Nanjing, China.
QiZhong YiPsychiatry Department, Xinjiang University Affiliated First Hospital, Urumqi, China.
Jun MaPsychiatry Department, Inner Mongolia Mental Hospital, Hulun Buir, China.
Jinan WangMedical Department, Lundbeck Pharmaceutical Information Consulting Co., Ltd., Beijing, China.
Jianmin ZhuoMedical Department, Xi'an Janssen Pharmaceutical Ltd., Beijing, China, chu9@its.jnj.com.
Cuili HuMedical Department, Xi'an Janssen Pharmaceutical Ltd., Beijing, China, chu9@its.jnj.com.
Janssen (Belgium) · BEBeijing Anding Hospital · CNHangzhou First People's Hospital · CNHebei Medical University · CNHulunbuir University · CNKunming Medical University · CNNanjing Brain Hospital · CNNational Institutes of Pharmaceutical Research and Development (China) · CNShangdong Agriculture and Engineering University · CNXiamen Chang Gung Hospital · CNXinjiang Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundAnxiety symptoms usually worsen depression and functional impairment. The present study was aimed to evaluate the impact of escitalopram on social function and quality of life in major depressive disorder (MDD) patients with anxiety symptoms. PATIENTS AND

methodsAdult MDD patients with functional impairment (Sheehan Disability Scale [SDS] score ≥9) and anxiety symptoms (Hamilton Anxiety Rating Scale [HAM-A] score ≥14) received escitalopram (10-20 mg/day) for 8 weeks. Symptom status was assessed by SDS, Quality of Life Enjoyment and Satisfaction Questionnaire-Short Form, Montgomery-Åsberg Depression Rating Scale (MADRS), HAM-A, and Quick Inventory of Depressive Symptomatology-Self Report scales. Safety was evaluated by treatment-emergent adverse events (TEAEs).

resultsOverall, 208 (79.7%) of 261 enrolled patients completed the 8-week treatment. Mean (SD) SDS and Quality of Life Enjoyment and Satisfaction Questionnaire-Short Form total scores were 17.4 (5.87) and 39.3 (14.43) at baseline, which improved to 7.6 (6.71) and 61.6 (15.80), respectively, at week 8. Totally, 59.2% of patients achieved functional remission (SDS≤6) and 61.7% of patients achieved depression remission (MADRS≤10) at week 8; 48.1% of patients achieved both functional and depression remission (SDS≤6 and MADRS≤10). The change in SDS total score was positively correlated with the change in MADRS and HAM-A total scores at each visit. Patient's baseline SDS score was related with depression score (regression coefficient=0.40582,

conclusionEscitalopram (10-20 mg/day) treatment was efficacious in reducing depression, improving social function, and quality of life in MDD patients with anxiety symptoms. No new safety signals were identified.

Indexed as

anxietyChineseescitaloprammajor depressive disordersocial function

Identifiers

PMID30147321
PMCPMC6097511
OpenAlexW2887345123

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.